Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Prospective, Multi-center, Double-blind, Placebo-controlled, Randomized, Multiple-arm, Parallel Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UthPeak NMNH (Reduced Nicotinamide Mononucleotide) in Healthy Adult Participants
Authors not listed
EffePharm LTD · 2024
Abstract
This study is to assess the safety and tolerability of NMNH as a dietary supplement for human consumption. The current study aims to comprehensively evaluate its potential effects on pharmacokinetics, physical performance, biological age and overall quality of life. These findings will expand our understanding of NMNH therapeutic potential and guide its future clinical applications in anti-aging interventions.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-05-31 MST
Cite this
APA
Anonymous. (2024). A Prospective, Multi-center, Double-blind, Placebo-controlled, Randomized, Multiple-arm, Parallel Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UthPeak NMNH (Reduced Nicotinamide Mononucleotide) in Healthy Adult Participants. <em>EffePharm LTD</em>. https://clinicaltrials.gov/study/NCT06889740
Vancouver
Anonymous. A Prospective, Multi-center, Double-blind, Placebo-controlled, Randomized, Multiple-arm, Parallel Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UthPeak NMNH (Reduced Nicotinamide Mononucleotide) in Healthy Adult Participants. EffePharm LTD. 2024.
BibTeX
@misc{anon2024AProsp,
title = {A Prospective, Multi-center, Double-blind, Placebo-controlled, Randomized, Multiple-arm, Parallel Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UthPeak NMNH (Reduced Nicotinamide Mononucleotide) in Healthy Adult Participants},
author = {Anonymous},
journal = {EffePharm LTD},
year = {2024},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Buck Institute for Research on Aging 2022
Open access · US-GOV
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Feasibility Pilot Study to Evaluate the Tolerability and Safety of a Novel Ketone Ester Ingredient in Healthy Older Men and Women.
SIPO Biotechnology Co. Ltd. 2027
Open access · US-GOV
A Randomized, Double-blind, Placebo-controlled Exploratory Clinical Study to Evaluate the Safety and Tolerability of SPOT-mRNA01 Injection in Healthy Adult Subjects.
Liaquat University of Medical & Health Sciences 2026
Open access · US-GOV
Effects of Ursolic Acid-Standardized Apple Pomace Extract Formulated With Phospholipids on Muscle Strength and Physical Performance in Older Adults With Mild Sarcopenia: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial
Chugai Pharmaceutical 2012
Open access · US-GOV
A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Gantenerumab Following Subcutaneous Injection in Japanese AD Patients
Chong Kun Dang Pharmaceutical 2019
Open access · US-GOV
An Open-label, Randomized, Multiple-dosing Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 With D797 and D324 in Healthy Subjects
ENCell 2027
Open access · US-GOV